StreetAlpha.app
Home › Stocks › BHVN

Biohaven Ltd. (BHVN)

Healthcare
$13.24
▼ −4.20%
LAST CLOSE · NOV 17

Biohaven is a New Haven, Connecticut biopharmaceutical company developing treatments for immune, nerve and metabolic diseases. It last closed at $13.24 on Nov 17, down 4.20% on the day. The average 12-month price target from 3 analysts is $20.33 (+53.6% from the last close), with a high of $32.00 and a low of $10.00. Analyst consensus is Hold, based on the latest ratings from 3 firms (1 buy, 2 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $1.1M, the largest $654K.

AI Auto Pilots
Is BHVN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$542.7M
EPS (diluted)
−$3.77
Free cash flow
−$473.2M
Valuation
Market cap
$2.0B
151.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$95.8M
At Sep 30
Debt
$264.3M
At Sep 30
Shareholder equity
−$98.2M
Shares outstanding
151.1M
At Oct 26
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: −$213.8M−$213.8MFY2021FY2022: −$570.3M−$570.3MFY2022FY2023: −$408.2M−$408.2MFY2023FY2024: −$846.4M−$846.4MFY2024FY2025: −$738.8M−$738.8MFY2025

From BHVN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Hold
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Hold
3firms
1 Buy2 Hold0 Sell
Each firm's latest rating on BHVN in the past 90 days
Average 12-month target
$20.33
▲ 53.6% upside

Based on 3 analysts who set a price target on BHVN in the past 90 days. The average target is $20.33, with a high of $32.00 and a low of $10.00, compared with the last close of $13.24.

Low $10.00Avg $20.33High $32.00
Blue marker: last close $13.24
Highest target$32.00
Average target$20.33
Lowest target$10.00
Latest rating changes
Canaccord GenuityMaintained
Oct 31Buy$32
HC Wainwright & Co.Reiterated
Sep 10Hold$10
RBC CapitalDowngrade
Sep 8Hold$19
Morgan StanleyMaintained
Aug 12Buy$19
B of A SecuritiesDowngrade
Jun 29Sell$11
DateFirmActionRatingPrice target
Oct 31Canaccord GenuityMaintainedBuy$32
Sep 10HC Wainwright & Co.ReiteratedHold$10
Sep 8RBC CapitalDowngradeHold$19
Aug 12Morgan StanleyMaintainedBuy$19
Jun 29B of A SecuritiesDowngradeSell$11
Loading…

Technical Analysis

BHVN · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 10% below its 20 day and 2% below its 50 day average. It is 7% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 44). The nearest support is the swing low (Jul 30) at $13.13, and the nearest resistance the Pivot at $13.44.

Short trendNeutral
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 7.4%/day
Key levels
$18.2452 week high+37.8%
$14.6220 day average+10.4%
$14.14100 day average+6.8%
$13.71Pivot R1+3.5%
$13.63Swing high (Sep 30)+2.9%
$13.4550 day average+1.6%
$13.44Pivot+1.5%
$13.24Last close
$13.13Swing low (Jul 30)−0.8%
$12.98Pivot S1−2.0%
$12.34200 day average−6.8%
$7.9952 week low−39.7%
Indicators
RSI (14)44.26Middle of its rangeNeutral
MACD0.16Below its signal lineBearish
Stochastic10.2Near the bottom of its rangeOversold
ADX (14)22.5Weak trend
Williams %R-98.2Oversold below −80, overbought above −20Oversold
CCI (20)-109.9Oversold below −100, overbought above 100Oversold
Rate of change−15.3%Change over 10 sessionsBearish
ATR (14)$0.98Typical daily range, 7.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for BHVN

What happened before

See how BHVN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow BHVN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How BHVN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in BHVN in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$1.1M
Largest print
$654K
Loading…

BHVN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●133 buying vs 133 selling
  • ●Held by funds -0.1 pts
  • ▲Funds holding +8
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding303295+2.7%
In funds' top 1089−11.1%
Held by funds93.5%93.6%−0.1 pts
New / increased48 / 8549 / 108−15.3%
Reduced / sold out95 / 3887 / 33+10.8%
Put/call ratio0.160.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BHVN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BHVN is in one of them and how their past BHVN trades turned out.

BHVN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BHVN in an article yet. Here's the latest on the wider market.

About Biohaven

Biohaven is a biopharmaceutical company based in New Haven, Connecticut. It develops treatments in immunology, neuroscience and oncology. Its main programs include a group of drugs that remove disease-causing proteins from the body for immune conditions such as Graves' disease and IgA nephropathy, a candidate for epilepsy, and a program for muscle and metabolic conditions, including obesity. Its treatments are aimed at patients with these diseases.

Headquarters
New Haven, CT